Irving Kron, MD & Victor Laubach, PhD Awarded $3.1 Million to Study Novel Perfusion-Based Therapies for Severe ARDS
Irving Kron, MD, and Vic Laubach, PhD, professors in the Department of Surgery, were awarded a 4-year, $3.1 million grant from the NIH to study groundbreaking, perfusion-based methods to treat severe acute respiratory distress syndrome (ARDS) or ischemia-reperfusion injury (IRI) after lung transplant. Both ARDS and IRI remain major clinical issues associated with high morbidity and mortality, and currently no methods exist for targeted treatment of injured lungs. Read the Full Story
This research will build upon recent discoveries, which were featured last month on CBS 19 News, UVA Health Newsroom, and UVA Today.
Lian-Wang Guo, PhD and Craig Kent, MD, Awarded $2.8 Million to Study Vascular Stenotic Disease
Lian-Wang Guo, PhD and Craig Kent, MD were recently awarded a R01 grant for $2.8 million from the NIH to study the epigenetic “writer” DOT1L, an enzyme that marks histone proteins with methyl groups, in vascular stenotic disease. Each year, over a million Americans receive open vascular reconstructions to restore blood flow to vital organs, but the grafts fail at high rates, and there are currently no FDA-approved methods to prevent graft failure.
Todd Bauer, MD Awarded $110,000 to Study Pancreatic Cancer Metastasis
Todd Bauer, MD recently received a one year multi-PI grant (PIs: Drs. Dave Kashatus and Todd Bauer) from the Lustgarten Foundation. The team received $110,000 for their study, “Elucidating the role of lipid droplets in pancreatic cancer metastasis.”
Jianjie Ma, PhD Awarded $100,000 to Study Treatment for Sepsis-Induced Lung Injury
Dr. Jianjie Ma was awarded $100,000 for his project, “Developing hCitH3-mAb to Treat Sepsis Induced Lung Injury” from the Commonwealth Commercialization Fund from the Virginia Innovation Partnership Corporation. In collaboration with HTIC, Inc., this VIPC proposal seeks to establish a production protocol for hCitH3-mAb following FDA guidelines and to conduct proof-of-concept studies using hCitH3-mAb to treat sepsis-induced acute lung injury in animal models. By proactively targeting the CitH3 pathway and utilizing advanced technologies for early detection and intervention, the hCitH3-mAb-based therapeutics represent a potential paradigm shift for the management and treatment of sepsis-ALI.